SSE/EFI Working Paper Series in Economics and Finance,
Stockholm School of Economics

Abstract: We study the choice of drug for the treatment of high blood pressure (hypertension) in Sweden between 1988-1994. During this time period calcium antagonists and ACE-inhibitors increased their market shares at the expense of the older drugs diuretics and beta-blockers. We use a prescription micro dataset where both patients and physicians can be followed over time---an important feature since it allows us to study the impact of physician preferences and patient habits on the choice of drug.

The choice of drug is unaffected by relative prices, indicating a moral hazard problem on the Swedish drug market characterized by a high degree of third-party financing. Physician preferences, measured as physician prescription history, are important for the choice of drug among new patients. Among existing patients the effect of physician preferences is mitigated by patient habit formation which slows down the diffusion of new drugs. Without habit effects the market share of calcium antagonists and ACE-inhibitors would have been more than 50% higher during our observation period (30% instead of the observed 19%).

Keywords: pharmaceuticals; physician behavior; habit formation; mixed logit estimator

JEL-codes: C25; I11; L10; O33

35 pages, First version: September 12, 2001. Revised: August 12, 2002.

Full text files

hastef0460.pdf  Full text

Download statistics

• Stockholm School of Economics
• Home page for this series

Questions (including download problems) about the papers in this series should be directed to Helena Lundin ()
Report other problems with accessing this service to Sune Karlsson ().

RePEc:hhs:hastef:0460This page generated on 2024-09-13 22:19:41.